Back

Bridging Genetics and Precision Medicine in Parkinson's Disease through GP2

Atterling Brolin, K.; Lange, L. M.; Navarro-Jones, E.; Jasaityte, S.; Ye Beh, Y.; Fang, Z.-H.; Iwaki, H.; Jones, L.; Klein, C.; Kleinz, T.; Leonard, H. L.; Mata, I.; Noyce, A.; Okubadejo, N. U.; Saffie Awad, P.; Screven, L.; Tan, A. H.; Toffoli, M.; Vitale, D.; Singleton, A.; Blauwendraat, C.; Nalls, M. A.; Morris, H.; the Global Parkinson's Genetics Program (GP2),

2026-03-28 neurology
10.64898/2026.03.26.26349418 medRxiv
Show abstract

In the Global Parkinson's Genetics Program (GP2) we aim to advance precision medicine by integrating large-scale clinico-genetic data from diverse populations worldwide. We investigated potentially trial-eligible carriers of pathogenic and high-risk GBA1 and LRRK2 variants and conducted a global precision-medicine survey across GP2 sites. Among 65,509 individuals with Parkinson's disease, we identified 9,019 (13.8%) potentially trial-eligible genetic variant carriers, including 6,789 GBA1, 2,084 LRRK2, and 146 dual GBA1-LRRK2 carriers. Individuals were distributed across multiple global regions, many of which currently lack active gene-targeted trials, highlighting a global disparity between relevant variant carriers and the availability of disease modifying treatment trials. GP2's unified framework supports equitable recruitment for gene-targeted therapeutic studies and helps address critical gaps in Parkinson's disease genetics and future therapeutic development.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.